Showing results 1 to 1 of 1
Title | Author(s) | Issue Date | Views | |
---|---|---|---|---|
First-line lorlatinib versus crizotinib in ALK-positive non-small cell lung cancer: Asian subgroup analysis of CROWN Proceeding/Conference:Annals of Oncology | 2021 | 29 |